{"doi":"10.1111/tid.70010","title":"Impact of Severe Persistent BK Polyomavirus on Graft Function and Quality of Life Outcomes in Kidney Transplant Recipients","abstract":"ABSTRACT Background The risk factors and outcomes associated with severe persistent BK polyomavirus (BKPyV) in kidney transplant recipients (KTR) are unknown. Methods This is a single‐center retrospective study of KTR with severe persistent BKPyV compared to (1) KTR with low/no BKPyV‐DNAemia and (2) KTR with high BKPyV‐DNAemia. Severe persistent BKPyV was defined as BKPyV load reaching > 6 log 10 (1 000 000 copies/mL) for ≥ 90 days. Low/no BKPyV was defined as BKPyV load remaining < 3 log 10 (1000 copies/mL), and high BKPyV was defined as BKPyV load ≥ 3 log 10 without meeting criteria for severe persistent BKPyV. Results Out of 2586 KTR, 22 had severe persistent BKPyV and were compared to 1843 KTR with low/no BKPyV and 721 KTR with high BKPyV. A low absolute lymphocyte count during the first month posttransplant was associated with an increased risk of severe persistent BKPyV relative to those with low/no BKPyV and high BKPyV (OR 0.91, 95%CI 0.84, 0.99). KTR with severe persistent BKPyV had significantly lower eGFR at 2 years posttransplant relative to low/no and high BKPyV groups eGFR (36 vs. 61 and 59 mL/min; p < 0.001 for both). Additionally, KTR with severe persistent BKPyV required more lab draws and incurred significantly higher total lab‐associated costs relative to KTR with low/no BKPyV and high BKPyV ($7516 vs. $4631, p < 0.001; $7516 vs. $5811, p < 0.001, respectively). Conclusions Severe persistent BKPyV is uncommon but associated with poor outcomes including impaired renal function, a higher burden of labs, and lab‐associated costs. Future studies are needed to determine underlying factors that predict severe persistent BKPyV.","journal":"Transplant Infectious Disease","year":2025,"id":543446,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9492,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1433089,"name":"Wairimu Magua","orcid":"0000-0002-0718-6464","position":1,"is_corresponding":false},{"id":408705,"name":"Geeta Karadkhele","orcid":"0000-0002-0267-9665","position":2,"is_corresponding":false},{"id":1266305,"name":"G. Tong Zhou","orcid":null,"position":3,"is_corresponding":false},{"id":914823,"name":"Payaswini Vasanth","orcid":null,"position":4,"is_corresponding":false},{"id":504868,"name":"Christian P. Larsen","orcid":"0000-0001-6573-2649","position":5,"is_corresponding":false},{"id":319849,"name":"Emily M. Eichenberger","orcid":"0000-0002-2469-0638","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T02:53:04.088079Z","pmid":"40099999","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}